絞り込み

16639

広告

Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells.

著者 Qi W , Davidson B , Nguyen M , Lindstrom T , Grey RJ , Burnett R , Aflaki E , Sidransky E , Westbroek W
Biochem J.2018 Dec 21 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (73view , 1users)

Full Text Sources

Medical

Gaucher disease is a rare lysosomal storage disorder caused by mutations in the gene, encoding the lysosome-resident glucocerebrosidase enzyme involved in the hydrolysis of glucosylceramide. The discovery of an association between mutations in and the development of synucleinopathies, including Parkinson disease, has directed attention to glucocerebrosidase as a potential therapeutic target for different synucleinopathies. These findings initiated an exponential growth in research and publications regarding the glucocerebrosidase enzyme. The use of various commercial and custom-made glucocerebrosidase antibodies has been reported, but standardized in-depth validation is still not available for many of these antibodies. This work details the evaluation of several previously reported glucocerebrosidase antibodies for western blot analysis, tested on protein lysates of murine and immortalized neurons and primary human wild type and type 2 Gaucher disease fibroblasts.
PMID: 30578288 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード